No significant differences were observed in the secondary end-points , including progression-free survival ( @ -LSB- @ % CI : @-@ @ -RSB- versus @ -LSB- @ % CI : @-@ @ -RSB- months ) and response rate ( @ % -LSB- @ % CI : @-@ @ -RSB- versus @ % -LSB- @ % CI : @-@ @ -RSB- ) .